DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Exclusion Criteria

• •Part I
• •1. A history of thyroid disease
• •2. A history of, or current liver disease, or liver injuries
• •3. Platelet count \<150,000/mcL
• •4. INR\> 1.2
• •5. History of, or current electrocardiogram (ECG) abnormalities, arrhythmias or heart valve diseases judged to be clinically significant by the investigator
• •Part II
• •1. A history of thyroid disease
• •2. Current or history of cirrhosis or decompensated liver disease
• •3. AST or ALT \> 5X ULN
• •4. DBIL \> ULN
• •5. Acute or chronic liver disease other than NAFLD
• •6. A history of bariatric surgery
• •7. HbA1c \>9.5% at screening
• •8. Testosterone or estrogen replacement therapy
• •9. Inducers or inhibitors of CYP3A4, including herbal therapies such as St John's Wort (CYP3A4 Inducer)